Wuhan Hvsen Biotechnology Co Ltd (300871) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.028x

Based on the latest financial reports, Wuhan Hvsen Biotechnology Co Ltd (300871) has a cash flow conversion efficiency ratio of 0.028x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥59.06 Million ≈ $8.64 Million USD) by net assets (CN¥2.12 Billion ≈ $309.94 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Wuhan Hvsen Biotechnology Co Ltd to measure how much of total assets are equity-financed.

Wuhan Hvsen Biotechnology Co Ltd - Cash Flow Conversion Efficiency Trend (2016–2025)

This chart illustrates how Wuhan Hvsen Biotechnology Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Wuhan Hvsen Biotechnology Co Ltd earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.

Wuhan Hvsen Biotechnology Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Wuhan Hvsen Biotechnology Co Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Chengdu Huaqi Houpu Holding Co Ltd SHE:300471	0.018x
Northpointe Bancshares, Inc. NYSE:NPB	0.064x
COPLAND ROAD CAPITAL NEW F:A2P	0.376x
Zhejiang Kingland Pipeline and Technologies Co Ltd SHE:002443	0.039x
Petrovietnam Camau Fertilizer VN:DCM	0.075x
Yunnan QuakeSafe Seismic Isolation Technologies Co Ltd Class A SHE:300767	0.032x
Endur ASA OL:ENDUR	0.060x
Guangzhou Haoyang Electronic Co Ltd SHE:300833	0.019x

Annual Cash Flow Conversion Efficiency for Wuhan Hvsen Biotechnology Co Ltd (2016–2025)

The table below shows the annual cash flow conversion efficiency of Wuhan Hvsen Biotechnology Co Ltd from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see 300871 stock market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	CN¥2.19 Billion ≈ $319.94 Million	CN¥238.45 Million ≈ $34.89 Million	0.109x	+267.07%
2024-12-31	CN¥1.47 Billion ≈ $214.41 Million	CN¥43.53 Million ≈ $6.37 Million	0.030x	-51.74%
2023-12-31	CN¥1.51 Billion ≈ $220.86 Million	CN¥92.92 Million ≈ $13.60 Million	0.062x	-1.84%
2022-12-31	CN¥1.54 Billion ≈ $225.56 Million	CN¥96.68 Million ≈ $14.15 Million	0.063x	-34.79%
2021-12-31	CN¥1.62 Billion ≈ $236.89 Million	CN¥155.72 Million ≈ $22.79 Million	0.096x	+174.38%
2020-12-31	CN¥1.38 Billion ≈ $201.81 Million	CN¥48.35 Million ≈ $7.08 Million	0.035x	-87.40%
2019-12-31	CN¥378.28 Million ≈ $55.35 Million	CN¥105.24 Million ≈ $15.40 Million	0.278x	+327.97%
2018-12-31	CN¥324.52 Million ≈ $47.49 Million	CN¥21.10 Million ≈ $3.09 Million	0.065x	-82.00%
2017-12-31	CN¥223.11 Million ≈ $32.65 Million	CN¥80.56 Million ≈ $11.79 Million	0.361x	-6.91%
2016-12-31	CN¥154.70 Million ≈ $22.64 Million	CN¥60.00 Million ≈ $8.78 Million	0.388x	--

About Wuhan Hvsen Biotechnology Co Ltd

SHE:300871 China Biotechnology

Market Cap

$594.39 Million

CN¥4.06 Billion CNY

Market Cap Rank

#11090 Global

#2959 in China

Share Price

CN¥20.13

Change (1 day)

-5.89%

52-Week Range

CN¥19.24 - CN¥32.62

All Time High

CN¥48.84